Valuation: Nuvectra Corporation

Market Cap 1.7M 1.49M 1.38M 1.27M 2.41M 163M 2.46M 16.54M 6.43M 79.62M 6.38M 6.24M 276M P/E 2017
-1.84x
P/E 2018 -5.02x
Enterprise Value -53.46M -46.89M -43.29M -40M -75.82M -5.12B -77.34M -520M -202M -2.5B -201M -196M -8.7B EV / Sales 2017
2.58x
EV / Sales 2018 4.76x
Free-Float
96.76%
Yield 2017 *
-
Yield 2018 -
Manager TitleAgeSince
Chief Executive Officer 78 31/01/2019
Compliance Officer 51 01/01/2015
Director TitleAgeSince
Director/Board Member 67 01/03/2016
Director/Board Member 78 01/03/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+16.67% - - 268K
-0.95%-1.20%-29.25%-11.93% 166B
+0.46%-0.77%-7.25%-4.51% 105B
-2.12%+2.32%+1.08%+57.34% 60.23B
+3.64%-4.34%+45.42%+51.88% 49.17B
-0.05%-4.73%-14.18%-41.52% 41.49B
+1.24%-5.36% - - 34.08B
-2.59%+1.05%-15.16%-44.88% 28.58B
+0.56%-2.73%+57.29%-5.71% 24.99B
-2.15%+3.29%-9.38%+3.10% 20.64B
Average -0.18%+3.07%+3.57%+0.47% 52.99B
Weighted average by Cap. -0.20%+2.11%-6.24%+0.95%

Financials

2017 2018
Net sales 31.84M 27.92M 25.78M 23.82M 45.15M 3.05B 46.06M 310M 120M 1.49B 120M 117M 5.18B 48.83M 42.83M 39.54M 36.54M 69.26M 4.68B 70.64M 475M 185M 2.29B 183M 179M 7.94B
Net income -44.6M -39.12M -36.12M -33.37M -63.26M -4.27B -64.52M -434M -169M -2.09B -167M -164M -7.25B -48.13M -42.22M -38.97M -36.02M -68.26M -4.61B -69.63M -469M -182M -2.26B -181M -177M -7.83B
Net Debt -1.49M -1.31M -1.21M -1.11M -2.11M -143M -2.16M -14.5M -5.64M -69.82M -5.6M -5.47M -242M -55.16M -48.38M -44.66M -41.27M -78.23M -5.28B -79.8M -537M -209M -2.58B -207M -203M -8.97B
Logo Nuvectra Corporation
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company's neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).
Employees
-
  1. Stock Market
  2. Stocks
  3. NVTRQ Stock